<DOC>
	<DOCNO>NCT00003214</DOCNO>
	<brief_summary>RATIONALE : Chemosensitizers may increase effectiveness chemotherapy drug make tumor cell sensitive drug . PURPOSE : Randomized phase III trial study effectiveness chemosensitivity test assign treatment patient stage III stage IV ovarian cancer undergone surgery .</brief_summary>
	<brief_title>Chemosensitivity Testing Assign Treatment Patients With Stage III Stage IV Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether use chemosensitivity assay assign treatment improve time progression response rate patient stage III/IV ovarian cancer . OUTLINE : This randomize study . Patients stratify accord size tumor debulking surgery , stage , Swiss Group Clinical Cancer Research center treatment receive . Within 14 day patient undergo debulking surgery , randomize one two treatment arm . Arm I : Patients randomize arm receive one six treatment regimen : Regimen A - cisplatin/cyclophosphamide Regimen B - cisplatin/cyclophosphamide/doxorubicin Regimen C - carboplatin Regimen D - carboplatin/cyclophosphamide Regimen E - cisplatin/paclitaxel Regimen F - carboplatin/paclitaxel Arm II : Patients randomize arm assign treatment regimen base chemosensitivity assay tumor specimen collect debulking surgery . If valid assay result obtain , patient receive carboplatin/cyclophosphamide . Treatment repeat every 3-4 week total 6 course . Up 4 course may administer partial response demonstrate . Patients follow every 3 month first 2 year every 6 month thereafter . PROJECTED ACCRUAL : Approximately 300 patient accrue study 6 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically/pathologically confirm stage III IV ovarian cancer Complete surgical stag debulking include total abdominal hysterectomy , bilateral salpingooophorectomy , omentectomy , biopsies suspicious lesion ( feasible ) require No low malignant potential histology without invasive lesion peritoneum PATIENT CHARACTERISTICS : Age : 80 Performance status : 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No disorder would prevent application protocol treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>